Ovid Therapeutics Inc.
OVID
$0.3383
-$0.0117-3.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 39.61% | -24.48% | 168.66% | 12.44% | -33.18% |
| Total Depreciation and Amortization | 14.29% | 15.75% | 8.03% | -6.21% | -68.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.81% | -43.90% | -1,801.88% | -347.48% | -119.59% |
| Change in Net Operating Assets | -123.34% | -6,117.24% | 507.79% | -544.44% | 5,627.99% |
| Cash from Operations | 15.98% | -49.29% | -21.78% | -37.76% | -29.81% |
| Capital Expenditure | -69.23% | 166.67% | -385.71% | -35.71% | 89.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 143.94% | 106.61% | -35.95% | -33.18% | -1,097.72% |
| Cash from Investing | 143.89% | 106.70% | -36.10% | -33.22% | -1,063.59% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -83.04% | 68.72% | 240.30% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -83.04% | 68.72% | 240.30% | 68,983.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -200.00% | 200.00% | -- |
| Net Change in Cash | 137.13% | -3.45% | -112.58% | -79.48% | -127.01% |